Date: 2016-04-20
Type of information: Financing round
Company: PeptiMimesis (France)
Investors: Cap Innov’Est (France)
Amount: €1.2 million ($1.4 million)
Funding type: financing round
Planned used: PeptiMimesis will use this funding to initiate its research activities on the design and characterization of transmembrane peptides. PeptiMimesis aims to rapidly identify peptide candidates acting on validated targets in oncology, immuno-oncology and autoimmune diseases.
Others: * On April 20, 2016, PeptiMimesis announces the release of the €0.5m ($0.6m) first tranche of a €1.2m ($1.4m)
investment made by Cap Innov’Est, a regionally-based seed fund. Created in October 2015, PeptiMimesis is a biopharmaceutical company based in Strasbourg, dedicated to the discovery and development of transmembrane
therapeutic peptides. The company’s proprietary platform will deliver a set of drug candidates that act on validated targets in the field of immuno-oncology, oncology and immune diseases. PeptiMimesis has recently signed its first collaboration deal withIpsen and is looking to establish further partnerships on its unique technology with pharma and biotech companies.
Therapeutic area: Autoimmune diseases - Cancer - Oncology
